WISP-1 (Wnt-1-induced secreted proteins), CCN5/WISP-2 and CCN6/WISP-3 [1] [2] [3] [4] . Each member of the family shares several modules that are homologous with other proteins: insulin-like growth factor-binding protein (IGFBP), von Willebrand type C domain (VWC), thrombospondin-1 (TSP-1) and cysteine knot, which exhibit various cellular functions such as cell adhesion, migration, apoptosis and angiogenesis [3, 5] . CYR61, as well as the other CCN members, is a secretory protein and associates with the extracellular matrix (ECM) and several integrins at the cell surface [6] . Moreover, it has been reported that CYR61 acts to mediate cell adhesion, stimulate chemostasis, augment growth factor-induced DNA synthesis, foster cell survival and enhance angiogenesis [6] [7] [8] [9] .
CYR61 is also involved in tumorigenesis, but exerts contrary effects in different tumor types. It stimulates tumor progression in breast cancer, pancreatic cancer and glioma [10] [11] [12] [13] [14] , while its expression is downregulated in prostate cancer, uterine leiomyoma, rhabdomyosarcoma and non-small-cell lung carcinoma [15] [16] [17] [18] .
Previously, we identified various up-or downregulated proteins specific to gastric carcinomas by proteomic analysis using resected human stomach tissues [19] . CYR61 was identified as a cancer-specific downregulated protein, and the downregulation of CYR61 function via interaction with the ECM or integrins might be associated with gastric carcinogenesis. So far, few reports have examined the expression and distribution of CYR61 in gastric mucosa and carcinoma.
In this study, we examine the expression of CYR61 and its clinicopathological significance in human gastric nonneoplastic mucosae, adenomas and carcinomas. Furthermore, we present evidence that the expression of CYR61 is conversely associated with the expression of matrix metalloproteinase-7 (MMP-7/matrilysin) in advanced gastric carcinomas and gastric carcinoma cell lines. MMP-7, a member of the MMP protein family, plays a key role in cancer progression and was identified as the only differentially overexpressed gene in gastric carcinoma cells in comparison with normal cells among the MMP family in a DNA microarray analysis [20] .
Materials and Methods

Clinical Samples
Histological examinations were performed on 127 surgically resected gastric adenocarcinomas and 33 gastric adenomas obtained by endoscopic mucosal resection. In all cases, histological type was classified according to the criteria of the Japanese Gastric Cancer Association [21] . In this study, papillary and tubular adenocarcinomas were classified as intestinal-type tumors, while poorly differentiated adenocarcinomas and signet-ring cell carcinomas were classified as diffuse-type tumors. All the specimens were extracted from the files of the Division of Organ Pathology, Faculty of Medicine, Tottori University and affiliated teaching hospitals. Approval for the study was obtained from the Institutional Review Board of the Faculty of Medicine, Tottori University (approval number 283). All the specimens were fixed with 10% formalin and embedded in paraffin. Sections 3 m thick were examined using immunohistochemistry.
Immunohistochemistry
Dewaxed paraffin-embedded sections were immunostained using the streptavidin-biotin peroxidase complex (SAB) method with a HISTOFINE SAB-PO (M) immunohistochemical staining kit (Nichirei, Tokyo, Japan). The primary antibodies used were as follows: a goat polyclonal antibody raised against CYR61 (1: 400, Santa Cruz Biotechnology, Santa Cruz, Calif., USA), a rabbit polyclonal antibody raised against serotonin (prediluted, Nichirei), a mouse monoclonal antibody raised against MMP-7 (1: 400, Daiichi Fine Chemicals, Takaoka, Japan), a rabbit polyclonal antibody raised against gastrin (prediluted, Nichirei) and a rabbit polyclonal antibody raised against somatostatin (prediluted, Nichirei). Immunoreactions were visualized with diaminobenzidine and the sections were counterstained with hematoxylin. At least 1,000 cancer cells in the tumor area with the highest CYR61 intensity were scored, and the percentage of cells showing positive staining was designated as the labeling index. The immunoreactivity of CYR61 protein was classified into 2 groups: negative, when less than 2% of tumor cells showed positive signals, and positive, when 2% or more tumor cells showed positive signals. MMP-7 immunoreactivity was also classified into 2 groups: negative, when there were 10% or less of tumor cells in areas where CYR61-positive cells were observed, and positive, when there were 10% or more tumor cells in these areas.
Dual-Color Immunofluorescence
Dewaxed paraffin sections were used for dual-color immunofluorescent staining. The sections were incubated with a goat polyclonal antibody raised against CYR61 (1: 400, Santa Cruz Biotechnology) at 4 ° C overnight. After being washed in PBS, the sections were incubated with a secondary FITC-conjugated anti-goat IgG antibody (1: 500, Sigma, St. Louis, Mo., USA) for 20 min at room temperature. After another wash in PBS, the sections were incubated with a rabbit polyclonal antibody raised against serotonin (prediluted, Nichirei) at 4 ° C overnight, followed by a biotinylated anti-rabbit IgG antibody for 20 min at room temperature. After that, the sections were incubated with a rhodamine-conjugated avidin (1: 500, Sigma) for 20 min at room temperature. After further washing, coverslips were placed on glass slides using water-soluble mounting medium. The slides were observed using fluorescence microscopy.
Cell Culture
Seven human gastric carcinoma cell lines were used in this study: MKN-1, adenosquamous carcinoma; MKN-7, well-differentiated adenocarcinoma; MKN-28 and MKN-74, moderately differentiated adenocarcinoma; MKN-45 and TMK-1, poorly differentiated adenocarcinoma, and KATO-III, signet-ring cell car-cinoma. All the cell lines were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin and 292 g/ml L -glutamine at 37 ° C in 5% CO 2 .
Western Blot Analysis SDS-PAGE and Western blotting were performed as described previously [22] . The membranes were blotted with the anti-CYR61 polyclonal antibody (1: 400, Santa Cruz Biotechnology), with the anti-MMP-7 monoclonal antibody (1: 400, Daiichi Fine Chemicals), or with the anti-␤ -actin monoclonal antibody (1: 2,000, Sigma). Signals were visualized with an enhanced chemiluminescence system (ECL Detection System; Amersham Pharmacia Biotech, Piscataway, N.J., USA).
Statistical Analysis
Statistical analyses were performed using Student's t test, Fisher's exact probability test, Mann-Whitney's U test or the 2 test. Values were considered to be significantly different when p ! 0.05.
Results
Expression of CYR61 in Normal Gastric Mucosa, Intestinal Metaplasia, Adenoma and Carcinoma
Immunohistochemistry showed that CYR61 protein was mainly present in the cytoplasm, and CYR61-positive cells were distributed in the lower half of the gastric mucosa ( fig. 1 a) . The CYR61-positive cells were similar to serotonin-containing enterochromaffin (EC) cells ( fig. 1 b) . This was confirmed using a dual-color immunofluorescence technique which showed double staining of CYR61-positive and serotonin-positive cells ( fig. 1 c-e ).
In addition, no immunoreactivity was noted in stromal cells, including lymphocytes. In gastric intestinal metaplasia, adenomas, and early carcinomas, the distribution of CYR61-positive cells was similar to that of serotonin-containing cells ( fig. 2 a-f) , as is the case in normal mucosa. On the other hand, in advanced gastric carcinoma, the number of CYR61-positive cells was slightly smaller than that of serotonincontaining cells, and some of the serotonin-positive carcinoma cells were consistent with CYR61-expressing cells ( fig. 2 g, h) . Table 1 shows the frequency of CYR61 expression in the 33 gastric adenomas and the 127 carcinomas. The cutoff level of the CYR61 labeling index in tumor cells was fixed at 2%, which was almost the median for all the carcinoma cases. All the adenomas were classified into the positive group, the frequency being significantly higher than in the 127 carcinomas (p ! 0.001). Moreover, the frequency was significantly higher in the 49 early carcinomas than in the 78 advanced carcinomas (p ! 0.001). Furthermore, all of the normal gastric mucosae or intestinal metaplasias were categorized as positive. These findings suggest that a downregulation of CYR61 expression might be associated with gastric carcinogenesis and the progression of cancer.
Correlation between CYR61 Expression and Clinicopathological Parameters in 127 Gastric Cancers
The immunohistochemical expression of CYR61 and its correlation with clinicopathological features in the 127 gastric carcinomas are summarized in table 2 . CYR61 expression was positive in 62 carcinomas, and negative in 65 carcinomas. Positive expression was significantly higher in intestinal-type than diffuse-type tumors (p ! 0.05). Moreover, positive CYR61 expression in gastric carcinomas was correlated with a more malignant phenotype including depth of invasion (p ! 0.001), lymphatic invasion (p ! 0.001), venous invasion (p ! 0.001), lymph node metastasis (p ! 0.001) and clinical stage (p ! 0.001).
Correlation between the Expression of CYR61 and MMP-7 in Gastric Carcinomas
As mentioned above, downregulation of CYR61 expression enhanced the ability of cellular invasion in gastric carcinoma cells. It is known that the various factors are implicated in the invasion of gastric cancer cells. Of these, the expression of MMP-7, a member of MMP family, was strongly associated with tumor invasion in gastric carcinoma as reported by Kitoh et al. [23] , who examined MMP-7 expression immunohistochemically and revealed 
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Oncology 2007;73: [118] [119] [120] [121] [122] [123] [124] [125] [126] 123 that the expression of MMP-7 was significantly correlated with depth of invasion and vascular invasion. Thus, we targeted MMP-7 to examine whether the reduction in CYR61 expression correlated with MMP-7 expression in the 78 advanced carcinomas. The expression of MMP-7 was not found around the CYR61-expressing cells ( fig. 3 a, b) . On the other hand, MMP-7 was clearly expressed in the tumor cells, where the CYR61-negative tumor cells were localized ( fig. 3 c,  d ). Table 3 shows the relationship between CYR61 and MMP-7 expression in the 78 advanced gastric carcinomas. Eleven of the 19 CYR61-positive cases (57.9%) were negative for MMP-7 expression, while 40 of the 59 CYR61-negative cases (67.8%) were positive for MMP-7. Thus, a significant inverse correlation was found between the histological expression of CYR61 and MMP-7 (p ! 0.001).
As shown in figure 4 , Western blotting revealed that CYR61 protein was clearly expressed in MKN-1, MKN-7, MKN-28, MKN-74 and slightly expressed in TMK-1. On the other hand, MMP-7 was strongly expressed in MKN-45 and KATO-III, where no expressions of CYR61 were observed. These results indicated that the expression of MMP-7 was conversely associated with that of CYR61, even in the gastric carcinoma cell lines.
Discussion
Our data showed that CYR61 was expressed in epithelial cells and tumor cells, but not in mesenchymal cells, including lymphocytes. Hence, the downregulation of CYR61 expression, previously identified by proteomics [19] , indicates that the level of CYR61 was markedly reduced in the gastric carcinoma cells compared to nonneoplastic epithelial cells. In the present study, CYR61-positive cells coincided with serotonin-containing cells not only in the nontumoral mucosae, but also in the adenomas and carcinomas. We previously reported that: (i) serotonin-containing cells were distributed in the lower half of the gastric mucosa and also in gastric tumors and (ii) the incidence of the serotonin-containing tumor cells decreased with the depth of tumor invasion in human gastric carcinomas [24, 25] . The present study also confirmed that the frequency of CYR61-positive tumors was significantly lower in the advanced carcinomas than in the early carcinomas. Taken together, it is suggested that CYR61 and serotonin were probably secreted from the same cells, and they play roles in the proliferation and differentiation of gastric epithelia or tumor cells.
All the nontumor mucosae and adenomas were classified as positive for CYR61 expression, while about half of the gastric carcinomas fell into the negative expression category. Moreover, it is noteworthy that CYR61 expression was drastically reduced in the advanced carcinomas compared to early carcinomas. Thus, the downregulation of CYR61 expression could partly contribute to the progression of gastric carcinoma. Reduced expression of CYR61 in gastric carcinomas was significantly associated with several clinicopathological factors including depth of invasion, vessel invasion, lymph node metastasis and clinical stage. The decline in the expression of CYR61 was also related to the histological grading of the gastric carcinoma. Zheng et al. [26] reported that the diffuse-type carcinoma was more inclined to invasion into muscularis propria, lymphatic invasion and lymph node metastasis. Taken together, it is suggested that the reduction of CYR61 expression might be a marker predicting cancer cell invasion in gastric carcinoma.
Interestingly, the present study found MMP-7 as a candidate gene directly or indirectly regulated by CYR61 in gastric carcinoma. The MMP family plays a key role in cancer invasion and metastasis through the degradation of ECM components in a wide range of malignant tumors [27] . MMP-7 is considered to have a direct role in the progression of cancer [28, 29] . Over 20 enzymes of the MMP family have been identified [30] , with MMP-7 showing the highest level of activity [31] . MMP-7 is produced by the cancer cell itself and plays a central role in the degradation of the ECM, including type IV collagen [23, 32, 33] . A recent report suggested that MMP-7 expression was related with tumor invasion in advanced gastric carcinoma [34] . It is also known that the expression of MMP-7 is promoted by E1AF, an Ets family transcription factor, in human gastric carcinoma [35] . On the other hand, CYR61 protein positively or negatively regulates various cellular functions including proliferation, differentiation, survival, adhesion and migration by interacting with integrin located at the cell surface [36, 37] . Mitra et al. [37] reported that ligation of cell surface ␣ v ␤ 1 integrin by anti-␣ v antibody led to the activation of focal adhesion kinase (FAK) and the expression of MMP-7 in a melanoma cell line, B16F10. It is also suggested that CYR61 might suppress MMP-7 expression by interacting with surface ␣ v ␤ 1 integrin to inhibit the activation of FAK and/or E1AF in gastric carcinoma cells. Although it is not well known how CYR61/CCN1 regulates the expression of MMP-7, Soon et al. [38] reported that expression of MMP-1, one of the MMP family members, was downregulated by WISP-1/CCN4 which belongs to the CCN family through inhibition of Rac activation in human lung cancer cells. Therefore, it is suggested that CYR61 might downregulate MMP-7 expression.
By contrast, Lin et al. [39] recently reported CYR61-activated tumor cell invasion via an integrin ␣ v ␤ 3 / NF-B-dependent pathway in AGS, a human gastric carcinoma cell line. The discrepancy might be partly explained by the differences in the integrins or cell lines used in each study.
In this study, we showed that (i) CYR61 is exclusively expressed in serotonin-containing cells in gastric epithelial and tumor cells and (ii) CYR61 might play a role in suppressing the invasion of gastric carcinoma cells by silencing the expression of MMP-7. In addition, the present results support the notion that CYR61 expression could be used to screen for patients with aggressive gas- tric cancer at the point of cancer invasion. Furthermore, CYR61 might be a molecular target in the clinical treatment of gastric cancer. Further in vitro studies will be required to elucidate the roles of CYR61 in gastric cancer invasion.
